Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Psilocybin - Filament Health

Next Previous
Drug Profile

Psilocybin - Filament Health

Alternative Names: PEX 010

Latest Information Update: 07 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Filament Health
  • Developer Filament Health; John Hopkins University; Psyence Group; Rigshospitalet; University of Calgary
  • Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Ethylamines; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phosphates; Phytotherapies; Small molecules
  • Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adjustment disorders; Alcoholism; Depressive disorders; Post-traumatic stress disorders
  • Phase I Traumatic brain injuries
  • Preclinical Anxiety disorders

Most Recent Events

  • 07 Sep 2025 Filament Health plans to initiate a phase II trial for Depressive disorders (Treatment-resistant) in Italy (PO) (CTIS2024-519844-34-03)
  • 31 Jul 2025 Filament Health announces the first-ever approval for compassionate use of psilocybin for Depressive disorders in European Union (EU)
  • 24 Jul 2025 The Medicines and Healthcare Products Regulatory Agency (MHPRA) approves two phase II trials in UK

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top